Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P520: Endoscopic evaluation and factors affecting the endoscopic efficacy during granulomonocytapheresis in moderately-to-severely active ulcerative colitis: a multi-centre retrospective study

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Yamamoto1, T. Iida2, K. Ikeya2, M. Kato2, A. Matsuura2, S. Tamura3, R. Takano3, S. Tani4, S. Osawa4, K. Sugimoto3, T. Shimoyama*1, H. Hanai2

1Yokkaichi Hazu Medical Centre, IBD Centre, Yokkaichi, Japan, 2Hamamatsu South Hospital, Center for Gastroenterology and Inflammatory Bowel Disease Research, Hamamastu, Japan, 3Hamamatsu University School of Medicine, First Department of Medicine, Hamamatsu, Japan, 4Hamamatsu University School of Medicine, Department of Endoscopic and Photodynamic Medicine, Hamamatsu, Japan

P521: Pre-operative enteral nutrition in adults with Crohn’s disease: effect on gut microbiota and disease outcomes

ECCO '19 Copenhagen

Year: 2019
Authors:

M. P. Costa Santos*1, C. Palmela1, J. Torres1, A. Ferreira1, S. Velho1, L. Glória1, S. Ouro1, I. Gordo2, M. Cravo1

1Hospital Beatriz Ângelo, Loures, Portugal, 2Instituto Gulbenkian de Ciência, Lisboa, Portugal

P522: Expression of markers of early atherosclerosis in inflammatory bowel disease: a prospective cohort of a single referral centre

ECCO '19 Copenhagen

Year: 2019
Authors:

B. Scrivo*1, M. G. Cilluffo1, A. Tuttolomondo2, D. Torres2, V. Calvaruso1, A. Pinto2, M. Cappello3

1University of Palermo, Gastroenterology Section, DiBiMis, Palermo, Italy, 2University of Palermo, Internal Medicine and Cardioangiology, DiBiMis, Palermo, Italy, 3University of Palermo - Italy, Gastroenterology Section, DiBiMis, Palermo, Italy

P523: Endoscopic balloon dilatation is safe and has a high success rate in patients with stricturing Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

E. Lim1,2,3, M. Thai2,4, P. Hendy2,4, M. Alchlaihawi5, R. Leong5,6,7, S. Connor6,8, W. Ng6,8, B. Gu6,8, D. van Langenberg9,10, L. Thin11,12, J. Schulberg13,14, M. Kamm13,14, R. Gilmore15, K. Taylor15, O. Sallis16,17, J. Andrews16,17, C. Daker18,19, M. Barclay18,19, G. Wark6,20, S. Ghaly6,20, M. Begun6, K. Krishnaprasad21, J. Begun*2,4,22

1Queen Elizabeth II Jubilee Hospital, Gastroenterology, Brisbane, Australia, 2The University Of Queensland, Faculty of Medicine, Brisbane, Australia, 3James Cook University, College of Medicine and Dentistry, Townsville, Australia, 4Mater Hospital Brisbane, Gastroenterology, Brisbane, Australia, 5Concord Repatriation General Hospital,, Sydney, Australia, 6University of New South Wales, Faculty of Medicine, Sydney, Australia, 7Macquarie University, Faculty of Medicine and Health Sciences, Sydney, Australia, 8Liverpool Hospital, Gastroenterology, Sydney, Australia, 9Eastern Health, Gastroenterology, Melbourne, Australia, 10Monash University, Faculty of Medicine, Nursing and Health Sciences, Melbourne, Australia, 11Fiona Stanley Hospital, Gastroenterology, Perth, Australia, 12University of Western Australia,, Faculty of Health and Medical Sciences, Perth, Australia, 13St Vincent’s Hospital, Gastroenterology, Melbourne, Australia, 14University of Melbourne, Faculty of Medicine, Dentistry and Health Sciences, Melbourne, Australia, 15The Alfred, Gastroenterology, Melbourne, Australia, 16Royal Adelaide Hospital, Gastroenterology, Adelaide, Australia, 17University of Adelaide, Faculty of Health and Medical Sciences, Adelaide, Australia, 18Christchurch Hospital, Gastroenterology, Christchurch, New Zealand, 19University of Otago, Department of Medicine, Christchurch, New Zealand, 20St Vincent’s Hospital, Gastroenterology, Sydney, Australia, 21QIMR Berghofer, Brisbane, Australia, 22Mater Research Institute - UQ, Brisbane, Australia

P524: Systematic review of calcineurin inhibitors (CNI) and vedolizumab (VDZ) combination therapy in acute severe ulcerative colitis (ASUC)

ECCO '19 Copenhagen

Year: 2019
Authors:

H. Lin*1, W-C. Lim1

1Tan Tock Seng Hospital, Gastroenterology and Hepatology, Singapore, Singapore

P525: The benefits of anti-TNF drug and antidrug antibody (ADAb) level monitoring in a DGH

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Matthews*1, I. London1, I. Reilly1, T. Maheswaren1, A. Lewis Williams1, S. Michail1

1Countess of Chester Hospital, Chester, UK

P526: Survey of adherence to treatment in inflammatory bowel disease: ENADEII STUDY

ECCO '19 Copenhagen

Year: 2019
Authors:

I. Alonso Abreu*1, O. Alarcón-Fernández1, M. Carrillo-Palau1, L. Ramos López1, J. P. Gisbert2, M. Chaparro2, P. Nos3, A. Jiménez Sosa4, E. Quintero Carrión1, GETECCU1

1Hospital Universitario de Canarias, Gastroenterology, Santa Cruz de Tenerife, Spain, 2Hospital Universitario La Princesa. IIS-IP, CIBEREHD, Gastroenterology, Madrid, Spain, 3Hospital Universitario La Fe, Gastroenterology, Valencia, Spain, 4Hospital Universitario de Canarias, Statistics, Santa Cruz de Tenerife, Spain

P527: Body image dissatisfaction is increased in inflammatory bowel disease compared with healthy matched controls but not diseased controls

ECCO '19 Copenhagen

Year: 2019
Authors:

H. Su*1, A. Chen1, S. Brown1, J. Alcantara1, D. Sim2, H. Myint1, P. Lilic1, S. Inns1,2

1Hutt Valley Hospital, Gastroenterology Department, Lower Hutt, New Zealand, 2University of Otago, Department of Medicine, Wellington, New Zealand

P529: Exposure–response relationship of vedolizumab subcutaneous treatment in patients with ulcerative colitis: VISIBLE 1

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Rosario1, D. Polhamus2, N. Dirks2, R. Lock3, X. Yao1, J. Chen1, C. Chen1, W. Sun1, B. Feagan4, W. Sandborn5, G. D’Haens*6

1Takeda Development Center Americas Inc., Cambridge, USA, 2Metrum Research Group, Tariffville, USA, 3Aucuba Sciences, Ltd.,, Canterbury, Kent, UK, 4Robarts Clinical Trials, Robarts Research Institute, University of Western Ontario, London, ON, Canada, 5University of California San Diego, La Jolla, USA, 6Amsterdam University Medical Centers, Amsterdam, The Netherlands

P530: Ultra-proactive therapeutic drug monitoring incorporating infliximab point-of-care testing with ad hoc dose adjustment reduces C-reactive protein levels in patients with IBD during infliximab maintenance treatment

ECCO '19 Copenhagen

Year: 2019
Authors:

P. Bossuyt*1,2, E. Hoefkens2, I. Geerts3, F. Verbiest4, E. Vermeulen3, A. Van Olmen2, L. Pouillon2

1University Hospitals Leuven, Catholic University of Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 2Imelda General Hospital, Department of Gastroenterology, Bonheiden, Belgium, 3Imelda General Hospital, Department of Laboratory Medicine, Bonheiden, Belgium, 4Imelda General Hospital, Central Hospital Pharmacy, Bonheiden, Belgium

P531: Efficacy of tofacitinib maintenance therapy for ulcerative colitis in remitting patients vs. patients with clinical response after 8 weeks of induction treatment

ECCO '19 Copenhagen

Year: 2019
Authors:

W. Reinisch*1, M. T. Osterman2, G. Doherty3, A. Marren4, D. A. Woodworth4, N. Lawendy4, K. Kwok5, E. Maller4, C. Su4

1Medical University of Vienna, Vienna, Austria, 2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, 3St Vincent's University Hospital, University College Dublin, Dublin, Ireland, 4Pfizer Inc., Collegeville, PA, USA, 5Pfizer Inc., New York, NY, USA

P532: Safety and efficacy of endoscopic dilation of small bowel Crohn’s disease strictures by balloon-assisted enteroscopy: pooled analysis of individual data from 210 patients

ECCO '19 Copenhagen

Year: 2019
Authors:

D. Bettenworth*1, A. Bokemeyer1, L. Kou2, R. Lopez2, B. P. Halloran3, M. Reeson3, S. Hosomi4, M. Kishi5, F. Hirai5, N. Ohmiya6, F. Rieder7,8

1University Hospital Münster, Department of Medicine B, Gastroenterology and Hepatology, Münster, Germany, 2Cleveland Clinic Foundation, Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland, USA, 3University of Alberta, Division of Gastroenterology, Edmonton, Canada, 4Osaka City University Graduate School of Medicine, Department of Gastroenterology, Osaka, Japan, 5Fukuoka University Chikushi Hospital, Chikushino, Inflammatory Bowel Disease Center, Fukuoka, Japan, 6Fujita Health University School of Medicine, Department of Gastroenterology, Toyoake city, Japan, 7Cleveland Clinic Foundation, Department of Gastroenterology, Hepatology and Nutrition, Digestive Disease Institute, Cleveland, USA, 8Cleveland Clinic Foundation, Department of Pathobiology, Lerner Research Institute, Cleveland, USA

P533: Ustekinumab therapeutic drug monitoring in Crohn’s disease patients with loss of response

ECCO '19 Copenhagen

Year: 2019
Authors:

V. Heron*1,2, T. Bessissow1, A. Bitton1, P. Lakatos1, E. Seidman1, A. Jain3, R. Battat1,4, P. Germain1, C. Lemieux1, W. Afif1

1McGill University Health Centre, Department of Gastroenterology, Montreal, Canada, 2Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, USA, 3Prometheus Laboratories Inc., San Diego, USA, 4University of California San Diego, Division of Gastroenterology, La Jolla, USA

P534: IBD-related malignancies observed in 2015–2018: 4 years’ results from the prospective nationwide Hungarian registry

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Milassin*1, M. Rutka1, K. Farkas1, A. Bálint1, R. Bor1, A. Fábián1, Z. Szepes1, T. Szamosi2, K. Szántó1, P. Miheller3, Z. Barta4, J. Banai2, Á. Kovács5, Á. Salamon6, L. Lakatos7, L. Lakner7, K. Palatka8, M. Papp9, E. Schafer2, J. Novák10, Z. Erdélyi11, Z. Kürti12, P. L. Lakatos12, P. Sarlós13, N. Szigeti14, G. Veres9, A. Zaránd16, A. Gelley17, Á. Vincze18, F. Nagy1, T. Molnár1

1University of Szeged, First Department of Internal Medicine, Szeged, Hungary, 2Military Hospital - State Health Centre, Budapest, Hungary, 3Semmelweis University, Second Department of Internal Medicine, Budapest, Hungary, 4University of Debrecen, Department of Gastroenterology, Department of Medicine, Clinical Centre, Debrecen, Hungary, 5Péterfi Sándor Utcai Hospital Centre, Budapest, Hungary, 6Tolna County Teaching Hospital, Department of Gastroenterology, Szekszárd, Hungary, 7Markusovszky Hospital, Department of Medicine and Gastroenterology, Szombathely, Hungary, 8University of Debrecen, Institute of Medicine, Department of Gastroenterology, Debrecen, Hungary, 9University of Debrecen, Division of Gastroenterology, Department of Internal Medicine, Debrecen, Hungary, 10Pándy Kálmán Hospital of Békés County, Gyula, Hungary, 11Department of Medicine, Csolnoky F. Province Hospital, Veszprém, Hungary, 12Semmelweis University, First Department of Internal Medicine, Budapest, Hungary, 13Unversity of Pécs, Division of Gastroenterology, First Department of Medicine, Pécs, Hungary, 14University of Pécs, Second Department of Internal Medicine, Pécs, Hungary, 16Semmelweis University, First Deparment of Surgery, Budapest, Hungary, 17Buda Hospital of the Hospitaller Order of Saint John of God, Budapest, Hungary, 18University of Pécs, First Department of Internal Medicine, Pécs, Hungary

P535: Azathioprine vs. mesalamine for prevention of post-operative clinical relapse in Crohn’s disease patients with severe endoscopic recurrence: data on efficacy and safety from an IG-IBD multi-centre randomised double-blind double-dummy trial

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Orlando*1, F. Mocciaro2, M. Ventimiglia1, S. Renna1, D. Scimeca2, A. Rispo3, M. L. Scribano4, A. Testa3, A. Aratari5, F. Bossa6, E. Angelucci7, S. Onali8, M. Cappello9, M. Giunta10, F. Castiglione3, C. Papi5, V. Annese6, L. Biancone8, A. Kohn4, R. Di Mitri2, M. Cottone11

1IBD Unit, Villa Sofia-Cervello Hospital, Palermo, Italy, 2Gastroenterology and Endoscopy Unit, ARNAS Civico-Di Cristina-Benfratelli Hospital, Palermo, Italy, 3Department of Gastroenterology, Federico II University, Naples, Italy, 4Gastroenterology Unit, San Camillo Forlanini, Rome, Italy, 5Department of Gastroenterology, San Filippo Neri Hospital, Rome, Italy, 6Department of Gastroenterology, IRCCS, Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo (FG), Italy, 7Department of Gastroenterology, Sapienza University, Rome, Italy, 8Department of Gastroenterology, Tor Vergata University, Rome, Italy, 9Department of Gastroenterology, Palermo University, Palermo, Italy, 10Gastroenterology Unit, Villa Sofia-Cervello Hospital, Palermo, Italy, 11Internal Medicine, Villa Sofia-Cervello Hospital, Palermo, Italy

P536: Thiopurine metabolite levels in pregnant IBD patients and infants following intrauterine thiopurine exposure

ECCO '19 Copenhagen

Year: 2019
Authors:

E. Flanagan*1, A. Ross1, A. L. Hamilton1, S. J. Bell1

1St Vincent's Hospital, Gastroenterology, Melbourne, Australia

P537: The impact of early disease control with vedolizumab on surgery rates among patients with Crohn’s disease: a post-hoc analysis of the GEMINI trials

ECCO '19 Copenhagen

Year: 2019
Authors:

P. Dulai*1, L. Peyrin-Biroulet2, K. Hahn3, N. Khalife4, D. Lindner5, K. Lasch6, D. Demuth7, H. Patel8, V. Jairath9

1University of California - San Diego, La Jolla, USA, 2Nancy University Hospital, Nancy, France, 3IQVIA, Cambridge, USA, 4IQVIA, London, UK, 5Takeda Pharmaceuticals International AG, Zurich, Switzerland, 6Takeda Pharmaceuticals USA, Inc., Deerfield, USA, 7Takeda International – UK Branch, London, UK, 8Takeda Pharmaceuticals International, Deerfield, USA, 9Western University, London, ON, Canada

P538: Vedolizumab is effective in real life paediatric inflammatory bowel disease: report from the prospective, multi-centre VEDOKIDS cohort study

ECCO '19 Copenhagen

Year: 2019
Authors:

Z. Shavit-Brunschwig1, O. Ledder1, G. Focht1, D. Urlep2, R. Lev-Tzion1, D. Marcus1, E. Broide3, A. Assa4, S. Hussey5, A. Yerushalmy-Feler6, A. Levine7, J. Markowitz8, C. Norden9, D. Turner*1

1Shaare Zedek Medical Center, The Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, Jerusalem, Israel, 2Children's Hospital University Medical Centre, Department of Gastroenterology, Hepatology and Nutrition, Ljubljana, Slovenia, 3Assaf Harofeh Medical Center, The Kamila Gonczarowski Institute for Gastroenterology and Liver Diseases, Beer Yaakov, Israel, 4Schneider Children's Medical Center, The Institute of Gastroenterology, Nutrition and Liver Diseases, Petah Tikva, Israel, 5Our Lady's Children's Hospital, Crumlin, National Centre for Paediatric Gastroenterology, Dublin, Ireland, 6Tel Aviv Sourasky Medical Center, ‘Dana-Dwek’ Children's Hospital, Pediatric Gastroenterology, Liver and Nutrition Unit, Tel Aviv, Israel, 7Wolfson Medical Center, Pediatric Gastroenterology and Nutrition Unit, Holon, Israel, 8Cohen Children's Medical Center of NY, Division of Pediatric Gastroenterology and Nutrition, New York, USA, 9Hvidovre University Hospital, Department of Paediatrics, Hvidovre, Denmark

P539: Impact of a multi-disciplinary team meeting for managing inflammatory bowel disease patients: professional practice analysis based on 869 cases

ECCO '19 Copenhagen

Year: 2019
Authors:

H. Del Arco1, P. Rivière1, F. Zerbib1, D. Laharie1, F. Poullenot1

1Bordeaux University Hospital, Gastroenterology and nutrition, Bordeaux, France

P540: Therapeutic drug monitoring in ustekinumab: which factors affect trough levels?

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Theeuwen*1, N. Provoost1, M. Koning1, A. Van der Meulen - de Jong1, D. J. A. Moes2, J. Maljaars1

1LUMC, Gastroenterology-Hepatology, Leiden, The Netherlands, 2LUMC, Department of Clinical Pharmacy and Toxicology, LEIDEN, The Netherlands